Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.53 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931315 | 1.00 | PIK3CA (0.53) | PIK3CAPIK3C3MEN1POLBKMT2A | |
| SCHEMBL931317 | 1.00 | PIK3CA (0.53) | PIK3CAPIK3C3MEN1POLBKMT2A | |
| SCHEMBL16858919 | 0.84 | PIK3CA (0.51) | PIK3CAPIK3C3PIK3R1 | |
| SCHEMBL931337 | 0.77 | PIK3CA (0.32) | PIK3CAPIK3C3 | |
| SCHEMBL930652 | 0.77 | PIK3CA (0.33) | PIK3CAPIK3C3PIK3R1 | |
| SCHEMBL16865841 | 0.77 | PIK3R1 (0.58) | PIK3CAPIK3R1 | |
| SCHEMBL930654 | 0.77 | PIK3CA (0.33) | PIK3CAPIK3C3PIK3R1 | |
| SCHEMBL16859083 | 0.77 | PIK3R1 (0.58) | PIK3CAPIK3R1 | |
| SCHEMBL930655 | 0.77 | PIK3CA (0.33) | PIK3CAPIK3C3PIK3R1 | |
| SCHEMBL931335 | 0.77 | PIK3CA (0.32) | PIK3CAPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655375-B1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2014-12-03 | — | — | EP | disclosed |
| EP-2655375-B1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2014-12-03 | — | — | EP | disclosed |
| US-8846670-B2 | 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846670-B2 | 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846670-B2 | 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8815853-B2 | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2014-08-26 | — | — | US | disclosed |
| EP-2448940-B1 | 6,7,8,9-tetrahydro-pyrimido{1,2-a} pyrimidin-4-one derivatives, their preparation and pharmaceutical use thereof | SANOFI SA (FR) | 2014-05-21 | — | — | EP | disclosed |
| EP-2448940-B1 | 6,7,8,9-tetrahydro-pyrimido{1,2-a} pyrimidin-4-one derivatives, their preparation and pharmaceutical use thereof | SANOFI SA (FR) | 2014-05-21 | — | — | EP | disclosed |
| US-20130289031-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2013-10-31 | — | — | US | disclosed |
| EP-2655375-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2013-10-30 | — | — | EP | disclosed |
| US-20120208810-A1 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208810-A1 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208810-A1 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| WO-2012085244-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-06-28 | — | — | WO | disclosed |
| EP-2448940-A2 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001113-A2 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011001113-A2 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289031-A1 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | DPYD, TYMP, DHPS | PIK3CA 192/4885PIK3C3 1318/4885MEN1 328/4885 |
| US-20120208810-A1 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | ALK, HAX1, HCLS1 | PIK3CA 3059/4885PIK3C3 3977/4885MEN1 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.